ACP
AXSM icon

Acuta Capital Partners’s Axsome Therapeutics AXSM Stock Holding History

Acuta Capital Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-6,000
Closed -$489K – 49
2020
Q4 		$489K Sell
6,000
-16,500
-73% -$1.23M 0.13% 49
2020
Q3 		$1.6M Sell
22,500
-67,500
-75% -$5.26M 0.44% 39
2020
Q2 		$7.41M Sell
90,000
-218,500
-71% -$16.8M 2.14% 18
2020
Q1 		$18.1M Sell
308,500
-299,000
-49% -$24.4M 8.8% 2
2019
Q4 		$62.8M Buy
607,500
+85,000
+16% +$3.43M 15.55% 1
2019
Q3 		$10.6M Buy
522,500
+85,000
+19% +$2.18M 7.63% 6
2019
Q2 		$11.3M Buy
+437,500
New +$8.77M 4.01% 9

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Acuta Capital Partners's AXSM Position: Q1 2021 in Review

Acuta Capital Partners sold out of Axsome Therapeutics (AXSM) in Q1 2021, closing a stake of 6,000 shares — an estimated $489K sold.

Acuta Capital Partners first reported a position in AXSM in Q2 2019 and held it in 7 quarters. The position peaked at $62.8M in Q4 2019. 184 funds tracked by Wall St. Rank hold AXSM as of Q1 2021.

  • Acuta Capital Partners reported no remaining Axsome Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Acuta Capital Partners sold 6,000 Axsome Therapeutics shares in Q1 2021, an estimated $489K.
  • Acuta Capital Partners first reported a position in Axsome Therapeutics in Q2 2019 and held it in 7 quarters.
  • Acuta Capital Partners's Axsome Therapeutics position peaked at $62.8M in Q4 2019.
  • 184 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2021.

Based on Acuta Capital Partners's 13F filing for Q1 2021, filed 17 May 2021.